These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 12138046

  • 21. Valsartan in chronic heart failure.
    Cayley WE.
    N Engl J Med; 2002 Apr 11; 346(15):1173-4. PubMed ID: 11951861
    [No Abstract] [Full Text] [Related]

  • 22. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
    MMW Fortschr Med; 2006 Feb 02; 148(5):48-9. PubMed ID: 16518941
    [No Abstract] [Full Text] [Related]

  • 23. Valsartan in chronic heart failure.
    Campbell DJ.
    N Engl J Med; 2002 Apr 11; 346(15):1173-4. PubMed ID: 11951863
    [No Abstract] [Full Text] [Related]

  • 24. Valsartan in chronic heart failure.
    Forfar JC, Munir S.
    N Engl J Med; 2002 Apr 11; 346(15):1173-4. PubMed ID: 11951862
    [No Abstract] [Full Text] [Related]

  • 25. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.
    Bremner AD, Baur M, Oddou-Stock P, Bodin F.
    Clin Exp Hypertens; 1997 Nov 11; 19(8):1263-85. PubMed ID: 9385475
    [Abstract] [Full Text] [Related]

  • 26. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 27. Valsartan in heart failure patients previously untreated with an ACE inhibitor.
    Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, Orlov VA, Olbinskaya LI, Bolshakova TD, Sullivan J, Spormann DO.
    Int J Cardiol; 1998 Aug 20; 65(3):239-46. PubMed ID: 9740480
    [Abstract] [Full Text] [Related]

  • 28. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 20; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 29. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN.
    Am J Cardiol; 2002 Nov 01; 90(9):992-3. PubMed ID: 12398968
    [No Abstract] [Full Text] [Related]

  • 30. Ask the doctor. I had a heart attack three years ago at age 78. My doctor started me on lisinopril, carvedilol, and aspirin. My total cholesterol is 190, and my LDL is 128. Should I be taking a statin?
    Lee R.
    Harv Heart Lett; 2011 Aug 01; 21(12):7. PubMed ID: 21991614
    [No Abstract] [Full Text] [Related]

  • 31. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschr Med; 2003 Oct 23; 145(43):51. PubMed ID: 14664222
    [No Abstract] [Full Text] [Related]

  • 32. Bronchial hyperreactivity induced by angiotensin converting enzyme inhibitor.
    Goh TC, Ong YY.
    Singapore Med J; 1991 Jun 23; 32(3):183-4. PubMed ID: 1652161
    [Abstract] [Full Text] [Related]

  • 33. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.
    Circulation; 2006 May 09; 113(18):2201-10. PubMed ID: 16651474
    [Abstract] [Full Text] [Related]

  • 34. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr 09; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 35. [ESC guidelines for therapy of heart failure. AT1 blockers are now also included].
    MMW Fortschr Med; 2002 Jan 24; 144(3-4):62. PubMed ID: 11862800
    [No Abstract] [Full Text] [Related]

  • 36. Valsartan, captopril, or both in myocardial infarction.
    Jorde UP.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
    [No Abstract] [Full Text] [Related]

  • 37. Valsartan, captopril, or both in myocardial infarction.
    Moshenyat R, Kupfer Y, Tessler S.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
    [No Abstract] [Full Text] [Related]

  • 38. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M, Ross H, Levesque S, Whittom L, Pelletier GB, Racine N, Meloche S, Voisin L.
    Ann Pharmacother; 2009 May 26; 43(5):831-9. PubMed ID: 19417110
    [Abstract] [Full Text] [Related]

  • 39. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 26; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 40. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May 04; 148(18):42-3. PubMed ID: 16736689
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.